Compare NPK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | ABUS |
|---|---|---|
| Founded | 1905 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 983.1M | 884.7M |
| IPO Year | 1994 | 2008 |
| Metric | NPK | ABUS |
|---|---|---|
| Price | $145.12 | $4.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 66.4K | ★ 2.2M |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $388,228,000.00 | $6,171,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $139.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $77.63 | $2.71 |
| 52 Week High | $142.39 | $5.10 |
| Indicator | NPK | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 70.20 | 58.40 |
| Support Level | $102.66 | $4.18 |
| Resistance Level | N/A | $5.01 |
| Average True Range (ATR) | 5.74 | 0.22 |
| MACD | 0.92 | 0.03 |
| Stochastic Oscillator | 78.34 | 80.79 |
National Presto Industries Inc has an eclectic product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments namely Defense, Housewares/Small Appliance, and Safety. The defense segment which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases; performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances; the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.